Praxis Stock Soars 10% After Earnings — Its Quarterly Loss Widens

The drug developer has approximately $1.3 billion in cash and investments and is preparing for potential launches while FDA reviews remain pending.

Share
Praxis Stock Soars 10% After Earnings — Its Quarterly Loss Widens

Praxis Precision Medicines, which develops treatments for epilepsy and movement disorders, soared 10.34% to $306.32 in Monday trading, as of 10:32 a.m. ET, adding $801 million in market value after its earnings report. Its Monday corporate update detailed launch preparations while FDA reviews remained pending for essential-tremor treatment ulixacaltamide and epilepsy treatment relutrigine.

Launch Hiring Meets Wider Losses

Praxis is preparing for potential drug launches. Marcio Souza, president and CEO of Praxis Precision Medicines, said: "The relutrigine team is fully hired".

The third-quarter loss widened to $94.2 million from $73.9 million a year earlier. Stock-based compensation increased to $14.9 million from $7.4 million.

Praxis had approximately $1.3 billion in cash and investments at quarter-end. Management expects that money to fund operations into 2028.

An Epilepsy And Tremor Pipeline

Praxis uses genetic insights to develop medicines targeting imbalances in brain-cell activity. Its Cerebrum platform focuses on oral drugs; Solidus develops antisense oligonucleotides, medicines intended to change gene expression.

Its clinical-stage pipeline comprises four candidates. Alongside ulixacaltamide, relutrigine and elsunersen target severe genetic epilepsies, while vormatrigine targets common epilepsies.

Licensing agreements also form part of the business. UCB licensed PRAX-020, and Tenacia Biotechnology has an exclusive collaboration and license to develop and commercialize ulixacaltamide in China, Hong Kong, Macau and Taiwan.

A Rebound From Underperformance

Monday's advance put PRAX shares on pace for their biggest one-day gain since Aug. 6. Praxis's market value stood at about $8.6 billion in Monday trading.

Through Friday's close, the stock had lost 6% this year while the S&P 500 had gained 8%. Shares finished Friday 28% below their highest closing price of the past year.

Continuing losses were already part of that backdrop: Praxis reported a second-quarter net loss of $83.7 million.

Praxis is scheduled to hold its Investor Day on Thursday, with commercial strategy, launch readiness and its drug-development pipeline on the agenda.

Sources

More on Praxis Precision Medicines

All Praxis Precision Medicines (PRAX) coverage →